The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this spectrum of diseases. Determining which treatment approach is most appropriate for an individual patient requires careful consideration of unique clinical characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, these proceedings from 2 case-based CME satellite symposia held at the 2011 American Society of Hematology Annual Meeting attempt to provide the perspectives of clinical investigators on the evidence-based treatment of NHL, CLL and MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for NHL, CLL and MM.

LEARNING OBJECTIVES

NHL/CLL

• Appraise recent data on therapeutic advances and changing practice standards in NHL, and integrate this information, when appropriate, into current clinical care.
• Utilize prognostic and predictive clinical and molecular markers to aid in treatment decision-making for indolent and aggressive forms of NHL.
• Educate patients with follicular lymphoma and CLL about the indications for active treatment and the differential efficacy and safety of acceptable systemic regimens.
• Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of NHL.
• Develop an algorithm for the risk-stratified and age-appropriate induction treatment of diffuse large B-cell lymphoma and mantle-cell lymphoma.
• Apply the results of new research to the evidence-based treatment of T-cell lymphoma.
• Recall emerging data exploring novel agents and combinations with promising activity in diverse subtypes of NHL.
• Counsel appropriately selected patients about participation in ongoing clinical research studies.

MM

• Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, when appropriate, into current clinical care.
• Communicate the benefits and risks of post-transplant maintenance therapy to appropriately selected patients with MM.
• Recognize the treatment-associated side effects of immunomodulatory agents and proteasome inhibitors, and offer patients acceptable alternative dosing/administration options and/or supportive interventions to manage them.
• Effectively apply the results of pivotal clinical research to treatment options for elderly patients with newly diagnosed MM.
• Consider recent Phase III data on the frequency and duration of bisphosphonate therapy for patients with osteolytic and nonosteolytic MM.
• Employ case-based learning to individualize the use of maintenance and/or consolidation therapy in the management of MM.
• Recall emerging data exploring novel agents and combinations with promising activity in MM.
• Counsel appropriately selected patients about participation in ongoing clinical research studies.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

NHL/CLL

CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
These CME activities consist of video and interactive text components. The participant should watch the video content.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company and Mundipharma International Limited.

Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: April 2012
Expiration date: April 2013

Acknowledge and close

You may view the video proceedings from our satellite symposia at the 2011 ASH Annual Meeting here. To access interactive modules exploring faculty and audience responses to case-based premeeting surveys, please visit our full site at:ResearchToPractice.com/ASH12.